| Name | DR5 |
|---|---|
| Synonyms | Cell surface glycoprotein; MHC class I antigen; MHC class II antigen; DR5; Leucocyte antigen B; DR 5; DRB 1; DRB1… |
| Name | cycloheximide |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19538480 | Borel V, Marceau G, Gallot D, Blanchon L, Sapin V: Retinoids regulate human amniotic tissue-type plasminogen activator gene by a two-step mechanism. J Cell Mol Med. 2009 Jun 16. Furthermore, the use of cycloheximide revealed a two-step regulation of t-PA gene. Gene reporter assays confirmed, that the RA-induced t-PA gene expression occurred through interactions of retinoids receptors (RARs and RXRs) with a DR5 response element located at -7kb from the transcription site. |
2(0,0,0,2) | Details |
| 17692850 | Scherer GF, Zahn M, Callis J, Jones AM: A role for phospholipase A in auxin-regulated gene expression. FEBS Lett. 2007 Sep 4;581(22):4205-11. Epub 2007 Aug 3. In the presence of cycloheximide and excluding synthesis of IAA1:luciferase, ETYA had no apparent effect on degradation rates of IAA1, either with or without exogenous auxin. To identify the mode of action, rapid auxin-regulated gene expression was tested for sensitivity to these PLA (2) inhibitors using seedlings expressing beta-glucuronidase (GUS) under the control of the synthetic auxin-responsive promoter DR5. |
2(0,0,0,2) | Details |
| 17545621 | Ivanov VN, Zhou H, Hei TK: Sequential treatment by ionizing radiation and arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res. 2007 Jun 1;67(11):5397-407. We show in the present study that gamma-irradiation, as well as alpha-particle exposure, dramatically increases the susceptibility of melanoma cells to recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis via up-regulation of surface TRAIL-receptor 1/receptor 2 (DR4/DR5) levels and to Fas ligand-mediated apoptosis via up-regulation of surface Fas levels. |
1(0,0,0,1) | Details |
| 16003319 | Mori T, Doi R, Toyoda E, Koizumi M, Ito D, Kami K, Kida A, Masui T, Kawaguchi Y, Fujimoto K: Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery. 2005 Jul;138(1):71-7. The expression of TRAIL receptors (DR4, DR5, DcR1, and DcR2) and the expression of death signal-transducing proteins were investigated. In the TRAIL-resistant pancreatic cancer cells, effects of cycloheximide, a protein synthesis inhibitor, on death signal-transducing proteins were tested. |
1(0,0,0,1) | Details |
| 17044074 | Mahmutefendic H, Blagojevic G, Kucic N, Lucin P: Constitutive internalization of murine MHC class I molecules. J Cell Physiol. 2007 Feb;210(2):445-55. The total number of cell surface glycoprotein molecules at the plasma membrane results from a balance between their constitutive internalization and their egress to the cell surface from intracellular pools and/or biosynthetic pathway. In this study we have compared spontaneous internalization of murine major histocompatibility complex (MHC) class I molecules (K (d), D (d), full L (d), and empty L (d)) after depletion of their egress to the cell surface (Cycloheximide [CHX], brefeldin A [BFA]) and internalization after external binding of monoclonal antibody (mAb). |
1(0,0,0,1) | Details |
| 16465293 | Belloc F, Cotteret S, Labroille G, Schmit V, Jaloustre C, Dumain P, Durrieu F, Reiffers J, Boisseau MR, Bernard P, Lacombe F: Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines. Cell Death Differ. 1997 Dec;4(8):806-14. Apoptosis was studied in parental and mdr-1 expressing U937, HL60 and K562 myeloid leukemic cell lines using mdr unrelated inducers of apoptosis such as Ara-C, cycloheximide, serum deprivation, monensin and UV irradiation. The acquisition of this phenotype was posterior to the mdr-1 expressing phenotype since a HL60-DR5 variant, selected at the beginning of the induction of resistance, presented a low level of mdr-1 expression without resistance to apoptosis. |
1(0,0,0,1) | Details |
| 16123394 | Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, Jablons DM, Nishimura SL, Broaddus VC: A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol. 2005 Dec;33(6):541-8. Epub 2005 Aug 25. In 14-d-old spheroids, mesothelioma cells showed the same proliferation rate and expression of a death receptor, DR5, as in the original tumor. To determine responses to treatment, we treated tumor fragment spheroids grown from three separate tumors with agents, TNF-related apoptosis-inducing ligand (TRAIL) plus cycloheximide, that induced near total apoptosis in three human mesothelioma cell lines (M28, REN, MS-1) grown as monolayers (94 +/- 6% apoptosis; mean +/- SEM). |
1(0,0,0,1) | Details |
| 18362888 | Jeon YJ, Kim IK, Hong SH, Nan H, Kim HJ, Lee HJ, Masuda ES, Meyuhas O, Oh BH, Jung YK: Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling. Oncogene. 2008 Jul 17;27(31):4344-52. Epub 2008 Mar 24. Reduction of rpS6 expression in Jurkat and HeLa cells attenuated apoptosis induced by TRAIL, but not those by other cell death signals, including tumor necrosis factor-alpha and cycloheximide, etoposide, doxorubicin, tunicamycin and staurosporine. |
0(0,0,0,0) | Details |
| 15586230 | Vigneswaran N, Wu J, Nagaraj N, Adler-Storthz K, Zacharias W: Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis. Int J Oncol. 2005 Jan;26(1):103-12. The protein synthesis inhibitor cycloheximide markedly increased the TRAIL sensitivity of these cell lines, whereas the CB-specific chemical inhibitor CA-074 markedly reduced the sensitivity of primary OC cells to TRAIL. |
0(0,0,0,0) | Details |
| 17097066 | Lee TJ, Lee JT, Park JW, Kwon TK: Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP (L) and XIAP protein levels and ERK activation. Biochem Biophys Res Commun. 2006 Dec 29;351(4):1024-30. Epub 2006 Nov 7. The selected TRAIL-resistant cells were cross-resistant to TNF-alpha/cycloheximide but remained sensitive to DNA-damage drugs such as oxaliplatin and etoposide. |
0(0,0,0,0) | Details |
| 15806306 | Tanaka F, Kawakami A, Tamai M, Nakamura H, Iwanaga N, Izumi Y, Arima K, Aratake K, Huang M, Kamachi M, Ida H, Origuchi T, Eguchi K: IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression. Int J Mol Med. 2005 May;15(5):833-9. |
114(1,2,2,4) | Details |
| 15844877 | Jaganathan J, Petit JH, Lazio BE, Singh SK, Chin LS: Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines. Neurosurg Focus. 2002 Sep 15;13(3):ecp1. The A172 cells, by contrast, were susceptible only with cycloheximide, whereas U373MG cells were not susceptible to TRAIL. The selective tumoricidal activity of TRAIL is believed to be modulated by agonistic (DR4 and DR5) and antagonistic receptors (DcR1 and DcR2), which appear to compete for ligand binding. |
14(0,0,0,14) | Details |
| 18065493 | Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM: Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3219-28. Epub 2007 Dec 7. We show that TRAIL activates the canonical caspase-dependent pathway, whereas treatment with cycloheximide increases the sensitivity of MG-63 cells to TRAIL and anti-DR5 and can also sensitize hPOB-tert cells to both agents. |
32(0,1,1,2) | Details |
| 17051329 | McKee CM, Ye Y, Richburg JH: Testicular germ cell sensitivity to TRAIL-induced apoptosis is dependent upon p53 expression and is synergistically enhanced by DR5 agonistic antibody treatment. Apoptosis. 2006 Dec;11(12):2237-50. |
5(0,0,0,5) | Details |